Yisheng Biopharma Starts Clinical Trial of Novel Rabies Vaccine

Yisheng Biopharma, a China vaccine company, has begun a Phase I clinical trial of a novel therapeutic rabies vaccine in Singapore. The new vaccine uses a PIKA-based (stabilized double-stranded RNA) adjuvant that promotes both a humoral and cell-based response. As a result, Yisheng believes its rabies vaccine is more effective. The novel vaccine requires only three injections in seven days, as opposed to the usual regimen of five shots over 28 days. More details.... Share this with colleagues: // //